• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Codex DNA Inc. filed SEC Form 8-K: Leadership Update

    9/22/23 5:00:10 PM ET
    $DNAY
    Medical Specialities
    Health Care
    Get the next $DNAY alert in real time by email
    8-K
    false0001850079Telesis Bio Inc.00018500792023-09-202023-09-20

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 20, 2023

     

     

    TELESIS BIO INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40497

    45-1216839

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    10431 Wateridge Circle

    Suite 150

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 228-4115

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    TBIO

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (b)

    On September 20, 2023, William Snider informed the Board of Directors (the “Board”) of Telesis Bio Inc. (the “Company”) that he was resigning from the Board, including from the Board’s Audit Committee and Compensation Committee, effective on such date. Mr. Snider’s resignation was not the result of any disagreement with management or the Board. The Company is very grateful for Mr. Snider’s expertise and valuable contributions to the Company over the years.

    Also on September 20, 2023, the Board decreased the size of the Board to seven members as a result of Mr. Snider’s resignation and appointed Annette Tumolo to its Audit Committee and Compensation Committee.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    TELESIS BIO INC.

     

     

     

     

    Date:

    September 22, 2023

    By:

    /s/ Todd R. Nelson

     

     

     

    Name: Todd R. Nelson
    Title: Chief Executive Officer

     


    Get the next $DNAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNAY

    DatePrice TargetRatingAnalyst
    3/2/2022Outperform
    Cowen
    10/15/2021Outperform
    Cowen
    7/13/2021$23.00Buy
    Jefferies
    7/13/2021Outperform
    Cowen & Co.
    7/13/2021$30.00Overweight
    Keybanc
    More analyst ratings

    $DNAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Kullback William J

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      12/5/23 4:38:19 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Kullback William J

      3 - Telesis Bio Inc. (0001850079) (Issuer)

      12/5/23 4:36:40 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Herrema Gregory J. was granted 153,191 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      10/25/23 2:46:10 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen resumed coverage on Codex DNA

      Cowen resumed coverage of Codex DNA with a rating of Outperform

      3/2/22 8:41:22 AM ET
      $DNAY
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Codex DNA

      Cowen resumed coverage of Codex DNA with a rating of Outperform

      10/15/21 7:20:31 AM ET
      $DNAY
      Medical Specialities
      Health Care
    • Jefferies initiated coverage on Codex DNA with a new price target

      Jefferies initiated coverage of Codex DNA with a rating of Buy and set a new price target of $23.00

      7/13/21 6:31:09 AM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Financials

    Live finance-specific insights

    See more

    $DNAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

      -- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te

      11/8/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

      SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve

      11/2/22 4:19:04 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Codex DNA Reports Second Quarter 2022 Financial Results

      SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution across all areas of the growth strategy: Increased total revenue by 98% over prior year periodGrew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisitionDelivered solid growth in BioXp 3250 instrument placementsExperienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kitsLaunched MyBioXperience, a new e-commerce solution, which dramatically sim

      8/9/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

      -- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio's SOLA platform for enzymatic DNA synthesis technology SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022. The results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit. Telesis Bio also announced that it has a

      1/9/23 9:00:00 AM ET
      $DNAY
      $TBIO
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

      -- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te

      11/8/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

      SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve

      11/2/22 4:19:04 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    SEC Filings

    See more
    • Codex DNA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Telesis Bio Inc. (0001850079) (Filer)

      11/30/23 5:00:12 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Codex DNA Inc.

      10-Q - Telesis Bio Inc. (0001850079) (Filer)

      11/13/23 4:32:50 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Codex DNA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Telesis Bio Inc. (0001850079) (Filer)

      11/13/23 4:32:03 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Codex DNA Inc. (Amendment)

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      7/5/23 1:28:27 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Codex DNA Inc. (Amendment)

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      7/5/23 1:24:55 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form SC 13D filed by Codex DNA Inc.

      SC 13D - Telesis Bio Inc. (0001850079) (Subject)

      6/15/23 4:17:49 PM ET
      $DNAY
      Medical Specialities
      Health Care